Aeglea BioTherapeutics Provides Corporate Update and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
58
Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results

AUSTIN, Texas, May 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE ), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today provided a corporate update and reported financial results for the quarter ended March 31, 2018.

“The first quarter was a terrific start to our year, with a number of positive and encouraging developments in our lead clinical investigational program, pegzilarginase,” said Anthony G. Quinn, M.B Ch.B, Ph.D., interim chief executive officer of Aeglea. “I’m excited that we are seeing the first evidence that marked and sustained reductions in plasma arginine with pegzilarginase translated into clinically relevant treatment effects for two patients with Arginase 1 Deficiency. We plan to continue to build on this momentum by reporting additional repeat dose data in patients with Arginase 1 Deficiency in the third quarter of 2018 and finalizing our pivotal study design by the end of the year. In addition, we expect to report topline safety and clinical data from our cancer trials in the fourth quarter of 2018.

“Our April follow-on offering provides us with capital to continue to advance our planned operations and further develop our capabilities as we transition into a pivotal study and start planning for a commercial launch. Our strong cash position and our worldwide commercial rights for pegzilarginase position us favorably to build on recent clinical achievements with investments focusing on accelerating our clinical and pipeline programs.”

Corporate Update

Arginase 1 Deficiency:

  • Aeglea presented initial data that it believes demonstrated clinically relevant treatment effects with pegzilarginase in two Arginase 1 Deficiency patients after only eight weeks of dosing and confirmed the utility of standardized assessment tools in quantifying disease manifestations at the 2018 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics (ACMG) in April. This built upon data presented at the 2018 Annual Meeting of The Society for Inherited Metabolic Disorders (SIMD) that demonstrated pegzilarginase produces marked and sustained reductions in plasma arginine in patients with Arginase 1 Deficiency.   
  • Aeglea expects to report additional pediatric and adult repeat dose data in patients with Arginase 1 Deficiency in the third quarter of 2018.

Cancer:

  • Aeglea dosed the first patients with pegzilarginase in two small cell lung cancer (SCLC) trials: the single-agent Phase 1 cohort expansion and the Phase 1/2 combination trial with KEYTRUDA®, an anti-PD-1 therapy marketed by Merck (known as MSD outside the United States and Canada).
  • Aeglea presented Phase 1 dose escalation data regarding pegzilarginase in patients with advanced solid tumors at the 2018 Annual Meeting of the American Association for Cancer Research (AACR) in April.
  • The Company expects to report topline data, including safety and clinical activity, for the advanced solid tumor cohort expansions and the SCLC combination trial in the fourth quarter of 2018.
  • Aeglea expects to initiate Phase 2 of its combination trial for patients with SCLC in the third quarter of 2018.

Upcoming Events

Aeglea will participate and provide a corporate update at the UBS Global Healthcare Conference in New York, May 21-23, 2018.

First Quarter 2018 Financial Results

As of March 31, 2018, Aeglea had available cash, cash equivalents and marketable securities of $43.5 million, which excludes approximately $37.7 million in net proceeds from a follow-on public offering which closed on April 23, 2018. Based on Aeglea’s current operating plan, management believes it has sufficient capital resources to fund anticipated operations through the middle of 2020.

Aeglea recognized grant revenues of $1.5 million in the first quarter of 2018, compared with $1.0 million in the first quarter of 2017. The grant revenues were the result of a $19.8 million research grant received from the Cancer Prevention and Research Institute of Texas (CPRIT). The revenue increase was primarily due to higher qualifying expenditures associated with the clinical trials for pegzilarginase in cancer patients in the first quarter of 2018 compared with the first quarter of 2017.

Research and development expenses totaled $6.8 million for the first quarter of 2018, compared with $4.9 million for the first quarter of 2017. The increase was primarily due to expanded clinical activity for Aeglea’s lead product candidate, pegzilarginase, as Aeglea advanced a Phase 1/2 clinical trial in patients with Arginase 1 Deficiency and initiated three single-agent cohort expansions in advanced solid tumor patients and a Phase 1/2 combination trial with KEYTRUDA in patients with small cell lung cancer.

General and administrative expenses totaled $2.8 million for the first quarter of 2018, compared with $2.3 million in the first quarter of 2017. This increase was primarily due to additional employee headcount and compensation costs to further strengthen Aeglea’s management team and support expanding research and development activities.

Net loss totaled $8.1 million and $6.2 million for the first quarter of 2018 and 2017, respectively.

Inducement Grants

Aeglea also announced today that the Compensation Committee of its Board of Directors has granted non-qualified stock options to purchase an aggregate of 21,000 shares of Aeglea’s common stock to three new employees under Aeglea’s 2018 Equity Inducement Plan.

The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aeglea (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Aeglea, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

The options have an exercise price of $9.76 per share, which is equal to the closing price of Aeglea’s common stock on May 3, 2018. Each of the option awards vests as to 25% of the shares on the one-year anniversary of its grant, with the remainder of the shares vesting ratably over 36 months thereafter.

About Aeglea BioTherapeutics

Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com .

Safe Harbor / Forward Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our cash forecasts, the timing and success of our clinical trials and related data, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, success in our collaborations and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.                                          Media Contact: David Calusdian Sharon Merrill Associates 617.542.5300 AGLE@investorrelations.com  

Investor Contact: Charles N. York II Chief Financial Officer Aeglea BioTherapeutics investors@aegleabio.com

Financials

   
Aeglea BioTherapeutics, Inc. Condensed Consolidated Balance Sheets  
   
 (In thousands, except share and per share amounts)  
             
    March 31,     December 31,  
    2018     2017  
ASSETS                
CURRENT ASSETS                
Cash and cash equivalents   $ 10,760     $ 12,817  
Marketable securities     32,715       37,482  
Accounts receivable - grant     3,373       3,078  
Prepaid expenses and other current assets     1,995       1,614  
Total current assets     48,843       54,991  
Property and equipment, net     810       854  
Other non-current assets     133       232  
TOTAL ASSETS   $ 49,786     $ 56,077  
                 
LIABILITIES AND STOCKHOLDERS ’ EQUITY                
CURRENT LIABILITIES                
Accounts payable   $ 763     $ 389  
Deferred revenue     —       20  
Accrued and other current liabilities     5,002       5,220  
Total current liabilities     5,765       5,629  
Other non-current liabilities     101       111  
TOTAL LIABILITIES     5,866       5,740  
                 
STOCKHOLDERS’ EQUITY                
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2018 and December 31, 2017; no shares issued and outstanding as of March 31, 2018 and December 31, 2017     —       —  
Common stock, $0.0001 par value; 500,000,000 shares authorized  as of March 31, 2018 and December 31, 2017; 16,809,669 shares  and 16,670,188 shares issued and outstanding as of March 31, 2018  and December 31, 2017, respectively     2       2  
Additional paid-in capital     124,648       122,950  
Accumulated other comprehensive loss     (98 )     (102 )
Accumulated deficit     (80,632 )     (72,513 )
TOTAL STOCKHOLDERS’ EQUITY     43,920       50,337  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 49,786     $ 56,077  
   
Aeglea BioTherapeutics, Inc. Condensed Consolidated Statements of Operations  
   
 (In thousands, except share and per share amounts)  
       
    Three Months Ended March 31,  
    2018     2017  
Revenues:                
Grant   $ 1,510     $ 982  
                 
Operating expenses:                
Research and development     6,870       4,949  
General and administrative     2,885       2,364  
Total operating expenses     9,755       7,313  
Loss from operations     (8,245 )     (6,331 )
                 
Other income (expense):                
Interest income     143       95  
Other expense     (17 )     (11 )
Total other income     126       84  
Net loss   $ (8,119 )   $ (6,247 )
                 
Net loss per share, basic and diluted   $ (0.49 )   $ (0.47 )
Weighted-average common shares outstanding, basic and diluted     16,672,125       13,365,823  

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 264

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 317

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 367

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 414

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 217

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 238

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 121

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Van Horn Automotive Group Partners for Successful Dealership Sale

Updated Category News Views 928

Van Horn Automotive Group Sells Ford and Chevrolet Dealerships Performance Brokerage Services, recognized as a leader in dealership buy-sell transactions, has announced the acquisition of Van Horn Ford and Van Horn Chevrolet from Van Horn Automotive Group, marking an important transition for the dealerships. The new owners, Yelena and Alex Tovstanovsky of Sky Auto Mall,...

Continue Reading
G2 Goldfields Unveils Exciting Drilling Results at OKO

Updated Category News Views 136

G2 Goldfields Expands Mineral Resources at OKO G2 Goldfields Inc. (“G2”) (TSX: GTWO; OTCQX: GUYGF) has some exciting updates to share about its exploration activities at the vast 27,719-acre OKO-AREMU gold project. The company recently provided a significant update on their Mineral Resource Estimate (MRE), which now shows a remarkable total of 922,000 ounces of gold...

Continue Reading
Ecolectro Secures $10.5M Series A Funding for Green Hydrogen

Updated Category News Views 425

Ecolectro's Game-Changing Series A Funding Round Ecolectro has successfully completed a significant funding round, securing $10.5 million to enhance its innovative green hydrogen technology. The funding, led by Toyota Ventures, will enable Ecolectro to further develop its fully integrated and scalable electrolyzers, crucial for producing green hydrogen efficiently and...

Continue Reading
CEI Vision Partners Faces Data Breach Investigation: What to Know

Updated Category News Views 233

CEI Vision Partners Confronts Serious Data Breach Investigation In recent news, CEI Vision Partners, a prominent network of over 300 ophthalmologists and 700 optometrists, finds itself at the center of a significant data breach investigation. The investigation, led by the firm Schubert Jonckheer & Kolbe LLP, aims to uncover the details surrounding unauthorized access to...

Continue Reading
New Ethical AI Tools and Books Revolutionizing College Essays

Updated Category News Views 272

Innovative Solutions for College Essay Writing In light of recent prohibitions against artificial intelligence writing tools at major universities, students are navigating the challenges of crafting their college essays with greater scrutiny. College Essay Advisors has responded to this shift by introducing College EssAI, an innovative ethical AI platform designed to...

Continue Reading